Worse than that, Krantz and colleagues give no alternative clinical strategy to maintain treatment outcomes. Indeed, their current advice may even do the opposite if put into practice. Vague notions of avoiding methadone treatment or using lower doses would be as helpful as saying that patients with diabetes need to avoid insulin and, when unavoidable, should take only small doses. The only licensed alternative to methadone, buprenorphine, is simply not effective in a significant proportion of patients (2).